Product Name Bivalirudin Trifluoroacetate

Product Name Bivalirudin Trifluoroacetate
Sequence D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH
Cas No. 128270-60-0
Molecular Formula C98H138N24O33
Molecular Weight 2180.33
Purity (HPLC) 98.0%min.
Appearance? White Powder
Single Impurity (HPLC)? 1.0%max
Amino Acid Composition? ±10% of theoretical
Peptide Content (N%) ≥80.0%
Water Content (Karl Fischer)? ≤8.0%
TrifluoroAcetate Content(HPIC) ≤12.0%
MS (ESI) Consistent
Mass Balance? 95.0~105.0%

2. Description:
Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.
Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials.

3. Application:
Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).
Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.
Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.


至: HuBei YuanCheng SaiChuang Technology Co.,Ltd
Your E-mail:

Send to other suppliers

Other supplier products

Testosterone Cypionate
Testosterone Cypionate
Methenolone Enanthate
Methenolone Enanthate
Boldenone Undecylenate
Boldenone Undecylenate

Same products

Anesthetic Agents 98.5% L-Tryptophan
Anesthetic Agents 98.5% L-Tryptophan 卖方: HEBEI VICTORIA IMP.&EXP.CO.,LTD.
阿哌沙班 卖方: 杭州慧生生物医药科技有限公司 质量标准:内控质量标准   CAS 编码:503612-47-3
阿哌沙班 卖方: 杭州慧生生物医药科技有限公司 质量标准:内控质量标准   CAS 编码:503612-47-3
阿哌沙班 卖方: 杭州慧生生物医药科技有限公司 质量标准:内控质量标准   CAS 编码:503612-47-3
Ofloxacin with high quality
Ofloxacin with high quality 卖方: HEBEI VICTORIA IMP.&EXP.CO.,LTD.